Blog — Page 33

Iljin Hysolus (271940) Stock Outlook 2026: The Type-4 Hydrogen Tank Moat vs. the Fuel-Cell Reality

Iljin Hysolus (271940) Stock Outlook 2026: The Type-4 Hydrogen Tank Moat vs. the Fuel-Cell Reality

Iljin Hysolus (KOSPI 271940) 2026 stock outlook. A deep qualitative look at its Type-4 carbon-fiber hydrogen storage tank moat, single-customer concentration on Hyundai's Nexo and XCIENT, tube-trailer and defense diversification, disappointing FCEV demand, policy dependence, and why the stock trades as a leveraged option on the hydrogen economy for foreign investors.

Iljin Hysolus 271940 Korea Stocks
Kumho Tire (073240) Stock Outlook 2026: Raw-Material Spreads, EV Replacement Demand, and the Doublestar Overhang

Kumho Tire (073240) Stock Outlook 2026: Raw-Material Spreads, EV Replacement Demand, and the Doublestar Overhang

A deep 2026 analysis of Kumho Tire (KRX: 073240), the world's ~13th-largest tire maker. We break down the raw-material and FX cost cycle versus pricing power, the shift toward high-inch and EV-specific tires, US Georgia plus Vietnam and China plant utilization and tariff exposure, and the Chinese-owner Doublestar overhang left by its workout past. A cyclical value and turnaround name for foreign investors.

Kumho Tire 073240 Korea Stocks
Bicycle Accident Lawyer & Settlement 2026: Fault, Injury-Tier Payout Ranges, and How Insurance Actually Pays

Bicycle Accident Lawyer & Settlement 2026: Fault, Injury-Tier Payout Ranges, and How Insurance Actually Pays

A practical, attorney's-eye guide to bicycle-versus-car accident claims in the U.S.: how fault is decided when a cyclist is treated as a vehicle, settlement ranges by injury severity from road rash to traumatic brain injury, the order insurance pays (at-fault BI, then your own UM/UIM and PIP), hit-and-run and dooring cases, statute-of-limitations traps, and how contingency fees of 33 to 40 percent work.

bicycle accident personal injury comparative negligence
SMMT Summit Therapeutics Stock Outlook 2026: The Drug That Beat Keytruda, and Whether the Data Holds

SMMT Summit Therapeutics Stock Outlook 2026: The Drug That Beat Keytruda, and Whether the Data Holds

Summit Therapeutics (SMMT) stock analysis for 2026: ivonescimab's PD-1/VEGF bispecific mechanism, the head-to-head win over Keytruda in lung cancer, the Akeso license structure, single-asset concentration risk, the China-to-global data translatability question, and Robert Duggan's outsized role — a qualitative framework for a clinical-stage biotech.

SMMT Summit Therapeutics Ivonescimab